Q4 EPS Forecast for Puma Biotechnology Increased by Analyst

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Research analysts at Zacks Research lifted their Q4 2025 EPS estimates for shares of Puma Biotechnology in a note issued to investors on Wednesday, January 22nd. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn $0.16 per share for the quarter, up from their previous forecast of $0.13. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q2 2026 earnings at $0.01 EPS and Q3 2026 earnings at $0.11 EPS.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. The business had revenue of $80.50 million during the quarter, compared to analyst estimates of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same quarter in the prior year, the company posted $0.12 EPS.

A number of other equities analysts also recently issued reports on the stock. StockNews.com downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a research note on Monday, December 23rd.

Puma Biotechnology Stock Up 2.4 %

Shares of Puma Biotechnology stock opened at $3.02 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. Puma Biotechnology has a 12-month low of $2.22 and a 12-month high of $7.73. The company has a market cap of $148.25 million, a P/E ratio of 6.29 and a beta of 1.10. The company’s fifty day simple moving average is $3.05 and its two-hundred day simple moving average is $2.99.

Insider Transactions at Puma Biotechnology

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 33,841 shares of Puma Biotechnology stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $106,599.15. Following the completion of the transaction, the chief executive officer now owns 7,029,674 shares in the company, valued at approximately $22,143,473.10. The trade was a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $29,726.55. Following the completion of the sale, the insider now directly owns 108,951 shares in the company, valued at approximately $343,195.65. This represents a 7.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 23.70% of the company’s stock.

Institutional Investors Weigh In On Puma Biotechnology

Institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers boosted its stake in Puma Biotechnology by 2,309.9% during the 2nd quarter. Rhumbline Advisers now owns 50,270 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 48,184 shares during the last quarter. American Century Companies Inc. boosted its position in shares of Puma Biotechnology by 98.5% during the second quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock valued at $2,409,000 after buying an additional 366,653 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Puma Biotechnology by 6.6% during the second quarter. Dimensional Fund Advisors LP now owns 605,977 shares of the biopharmaceutical company’s stock valued at $1,975,000 after buying an additional 37,684 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Puma Biotechnology by 1.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,753,013 shares of the biopharmaceutical company’s stock worth $5,715,000 after buying an additional 23,600 shares in the last quarter. Finally, Squarepoint Ops LLC raised its position in Puma Biotechnology by 17.7% in the 2nd quarter. Squarepoint Ops LLC now owns 71,391 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 10,757 shares during the last quarter. Institutional investors own 61.29% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.